Megan Thomas

5 days ago | ddw-online.com | Megan Thomas

The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases.

6 days ago | ddw-online.com | Megan Thomas

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. News stories of note for this week include a major deal signed between Eli Lilly and Rznomics in the field of RNA-editing therapies, and a potential quality-of-life breakthrough for patients with Parkinson’s.

6 days ago | ddw-online.com | Megan Thomas

Biotech Tessera Therapeutics has presented updates across its in vivo genetic medicine programmes for Alpha-1 antitrypsin deficiency (AATD), Phenylketonuria (PKU), and Sickle Cell Disease (SCD), as well as advances in in vivo T cell therapies. These data were shared across four oral presentations and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, US, from 13-17 May 2025.

1 week ago | ddw-online.com | Megan Thomas

University of Queensland researchers have found that Gherlin, the natural ‘hunger hormone’, could be the key to preventing debilitating chronic constipation experienced by people living with Parkinson’s disease. Associate Professor Sebastian Furness from the UQ School of Biomedical Sciences said the team discovered the body’s receptor for Ghrelin had a critical role in the normal function of the spinal defecation centre – an area of the body in the lower spinal cord that controls bowel movements.

1 week ago | ddw-online.com | Megan Thomas

A new Introductory Guide is now available for download entitled ‘Unlocking the biopharma development pipeline‘. Discover a new generation of molecular sensing technology from Oxford Nanopore Technologies that is transforming the biopharma development pipeline. You’ll explore:How Oxford Nanopore sequencing overcomes challenges faced in the drug development processAdvantages of a single-platform solutionEnd-to-end workflows that can be applied to each stage of biopharmaceutical development